20 / 28
Veliparib + CHEMO improves ORR but not PFS/OS in
platinum-naive mBRCA MBC
Han H. SABCS 2016
Veliparib + Carbo-Taxol
Placebo + Carbo-Taxol
gBRCAm MBC
<2 previous lines
No prior platinum
Veliparib + TMZ
1:1:1
N=290
San Antonio Breast Cancer Symposium, December 6 - 10, 2016
Progression-Free Survival
Months Since Randomization
WƌŽďĂďŝůŝƚLJ ŽĨ
Progression-Free Survival
Number at risk
Placebo + C/P
Veliparib + C/P
98
95
82
80
61
60
35
38
20
22
8
13
4
4
0
2
0
1
Placebo + C/P
Veliparib + C/P
0.0
0.4
0.8
0.2
0.6
1.0
0
4
8
12
16
20
24
28
32
Median (95% CI) PFS, Veliparib + TMZ: 7.4 (5.9–8.5) months; HR = 1.858 (1.278–2.702), P = 0.001. (SABCS
program number: P4-22-02)
Placebo +
C/P
N = 98
Veliparib +
C/P
N = 95
HR
P
value
*
Median PFS,
months (95%
CI)
12.3
(9.3–14.5)
14.1
(11.5–16.2)
0.789
(0.536–
1.162)
0.231
TMZ/Vel was inferior
Placebo + C/P
N = 98
Veliparib + C/P
N = 95
ORR
61.3%
77.8%